0.05Open0.05Pre Close0 Volume107 Open Interest1.00Strike Price0.00Turnover91.63%IV17.98%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.3717Delta1.6967Gamma17.80Leverage Ratio-0.0016Theta0.0002Rho6.62Eff Leverage0.0009Vega
CytomX Stock Discussion
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
No comment yet